CCNB2过表达对非小细胞肺癌不良预后的预测效果研究

探讨细胞周期蛋白B2（CCNB2）在非小细胞肺癌（NSCLC）组织中的表达及对预后的影响。方法实时荧光定量聚合酶链反应和免疫组织化学法测定CCNB2 mRNA 和蛋白在NSCLC 肿瘤组织及临近非肿瘤组织中的表达水平，分析其与患者临床病理特征的关系。结果肿瘤组织中CCNB2 mRNA 和蛋白表达量高于非肿瘤组织（p <0.05），且其表达水平与肿瘤分化等级、直径、淋巴结转移、远处转移及临床分期呈正相关（p <0.05），同时CCNB2 高表达是患者生存率预后不良的危险因素。结论肿瘤组织中CCNB2 高表达与NSCLC 不良预后密切相关。

Cyclin B2 overexpression is a poor prognostic biomarker in NSCLC patients

To identify the role of cyclin B2 (CCNB2) in patients with NSCLC. Methods CCNB2 mRNA and protein expressions were detected in NSCLC and paracancerous tissues.Immunohistochemistry was used to detect the expression of CCNB2 protein in 186 NSCLC patients. The relationships between the expression of CCNB2 and clinicopathological features were analyzed. Results In this study, the expressions of CCNB2 mRNA and protein in the tumor tissues were higher than those in the nontumor tissues (p < 0.05). The expression levels of CCNB2 mRNA and protein were positively correlated with tumor differentiation grade, tumor diameter, lymph node metastasis, distant metastasis and clinical stage (p <0.05), while CCNB2 overexpression was a risk factor for low survival rate and poor prognosis of the patients.Conclusions The overexpression of CCNB2 in NSCLC is closely related to disease progression and poor prognosis, and CCNB2 could be severed as a marker of prognosis in patients with NSCLC.